Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Authors:

Top Cited Papers
Open Access
Abstract
Key Points: Nonmyeloablative, related HLA-haploidentical BMT utilizing high-dose posttransplantation cyclophosphamide has a favorable safety profile. Risk-stratified relapse and survival outcomes with this approach are comparable to those of HLA-matched BMT.

This publication has 36 references indexed in Scilit: